文章ID：3534

留学6年底薪两千

Adobe的人工智能原型可将物体粘贴到照片上同时添加逼真的照明和阴影_我的网站

四大名捕

A | CVS Health is planning to remove one type of a common decongestant from shelves after an advisory committee to the U.S. Food and Drug Administration said it was ineffective earlier this year.The products contain the oral formulation of phenylephrine (PE), which is found in several over-the-counter (OTC) medications.Although PE has been used as a decongestant for nearly a century, experts have been questioning its efficacy for years.The FDA Nonprescription Drugs Advisory Committee unanimously voted in September that PE did not improve nasal congestion any more than a placebo at the dosage given for OTC use.In response, CVS said it is removing products, in which PE is the only active ingredient from store shelves. This means products like Dayquil, which used a combination of active ingredients, will remain available for purchase."We are aware of the FDA Advisory Committee's position on oral phenylephrine (PE) and will follow direction from the FDA to ensure products we sell comply with all laws and regulations," CVS Health said in a statement. "We are removing certain oral cough and cold products that contain phenylephrine as the only active ingredient from CVS Pharmacy stores. Other oral cough and cold products will continue to be offered to meet consumer needs."CVS did not give specifies on brands that will be removed.The FDA told ABC News it has not yet determined whether it no longer considers PE to be a safe and effective medication and has not ordered the product to be removed from shelves. CVS's move is voluntary."The FDA has no further information to provide at this time regarding the timing of any decision the agency may make following the advisory committee meeting," the federal health agency said.The Consumer Healthcare Products Association told ABC News that the advisory committee's recommendation is a non-binding decision and not a change in regulation."FDA is currently in the process of reviewing the regulatory status of oral phenylephrine (PE) following September's advisory committee meeting," CHPA said in a statement. "Until FDA makes a determination on the committee's recommendation, oral PE remains a Category 1 OTC ingredient, which is generally recognized as safe and effective."Concerns were first raised about PE in 2007. Since then, evidence has accumulated showing that the drug offers little to no relief for nasal congestion.Experts believe this is because the body processes the drug before it reaches the nasal passages where it needs to work.It's unclear if other major retail pharmacy chains will follow in CVS's footsteps.Walgreens Boots Alliance would not disclose whether it was planning to remove products with PE from store shelves and said it would defer to the FDA."Walgreens follows FDA regulations. We are closely monitoring the situation and actively partnering with the Walgreens Office of Clinical Integrity and suppliers on appropriate next steps," a Walgreens spokesperson told ABC News.Other major pharmacy chains including Albertsons, Costco and Kroger did immediately reply to ABC News' request for comment. Walmart did not have an answer immediately available.ABC News' Sasha Pezenik and Sony Salzman contributed to this report.。更具体地说，它自动预测一个物体的比例，确定在图像中插入该物体的最佳位置，然后对该物体的颜色进行标准化处理，估计照明条件并生成符合图像美学的阴影。

B |
Adobe表示，合成可能是一个严重的手动、繁琐和耗时的过程。通常情况下，它涉及到寻找一个合适的物体或主题的图像，小心翼翼地将物体或主题从所述图像中切割出来，并编辑其颜色、色调、比例和阴影，使其外观与被粘贴到场景的其他部分相匹配。Adobe的Project Clever Composites消除了这一点。Adobe开发了一种更智能、更自动化的图像对象合成技术，采用了一种新的合成感知搜索技术，使用多个深度学习模型和数百万个数据点来确定语义分割、合成感知搜索、对象合成的标度位置预测、颜色和色调协调、照明估计、阴影生成。该系统还利用了一个单独的、基于人工智能的自动合成管道，负责预测物体的比例和位置，以便进行合成、色调正常化、照明条件估计和合成阴影。